DPX-Covid-19 is a slightly different vaccine approach compared to traditional approach. Credit: Jernej Furman.

Clinical-stage biopharmaceutical company IMV has announced that the government agencies of Canada will invest up to C$4.75m ($3.58m) in IMV’s Covid-19 vaccine candidate DPX-Covid-19.

IMV will receive C$4.15m ($3.12m) as part of the Canadian National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), as well as from the Canada Opportunities Agency and Next Generation Manufacturing Canada.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, IMV has received C$600,000 ($452,014) from the NRC IRAP’s innovative assistance programme.

IMV plans to use funds generated from the financing to support the scaling up of DPX-Covid-19 manufacturing and a Phase I study of DPX-Covid-19 in Canada.

DPX-Covid-19 is a slightly different vaccine approach compared to the traditional methods.

It combines the traditional vaccine approach with immunotherapy to generate a targeted immune response (IR) against the virus.

IMV CEO Frederic Ors commented: “Governmental organisations play a pivotal role in the fight against Covid-19.

“Their contribution allows IMV to leverage our innovative DPX platform for the rapid development of a vaccine to protect against the coronavirus.

“Vaccination is our best hope for ending the current pandemic. Based on our preclinical results and rapid development, we believe that both our vaccine and manufacturing approaches have the potential to be transformational for Covid-19, and we appreciate the governments’ support and confidence in our progress.”

In November 2018, IMV revised its Phase Ib/II clinical trial investigating the safety and efficacy of DPX-Survivac in combination with epacadostat for the treatment of patients with recurrent ovarian cancer.